-- Clinical data from OKI-219 PIKture-01 single agent and fulvestrant combination arms are maturing and is now expected to be reported together with initial data from the triplet expansion arms in the first quarter of 2026 -- Significant progress in next generation PI3Ka pan-mutant inhibitor program; multiple candidates identified - announcement planned for the first quarter of 2026 Exhibit 99.1 OnKure Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Business Update -- First patients ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 001-39685 INMED PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) British Columbia, Canada ...

Investment Income - Total investment income for Q3 2025 was $36.7 million, unchanged from Q3 2024[4] - Net investment income for Q3 2025 was $15.7 million, or $0.43 per share, compared to $15.9 million, or $0.41 per share in Q3 2024[6] - For the three months ended September 30, 2025, total investment income was $36,747,000, slightly up from $36,651,000 in the same period of 2024[33] - Net investment income for the three months ended September 30, 2025, was $15,736,000, compared to $15,875,000 for the same period in 2024[33] Investment Portfolio - The investment portfolio had an aggregate fair value of $0.9 billion, comprising $878.8 million in loans and $67.2 million in equity-related investments[10] - The dollar-weighted annualized yield on average debt investments for Q3 2025 was 16.8%[5] - Total investments at fair value were $945,964,000, down from $1,076,840,000, with non-control/non-affiliate investments valued at $931,915,000[31] Financial Position - As of September 30, 2025, total assets amounted to $963,346,000, a decrease from $1,091,355,000 as of December 31, 2024[31] - Net asset value per share decreased by 0.8% to $13.55 as of September 30, 2025[13] - The net asset value per share as of September 30, 2025, was $13.55, down from $13.79 as of December 31, 2024[31] - Total liabilities decreased to $473,820,000 from $576,486,000 as of December 31, 2024[31] - The company’s credit facility debt was $186,000,000, reduced from $311,000,000[31] Investment Activity - The company completed 11 investments totaling $128.3 million during the quarter[7] - Net realized loss on investments was $1.3 million for Q3 2025, compared to no net realized gains or losses in Q3 2024[8] - The company reported a net increase in net assets resulting from operations of $8,019,000 for the three months ended September 30, 2025[33] Liquidity and Dividends - As of September 30, 2025, the company had approximately $371.9 million in available liquidity[14] - The company declared a fourth quarter 2025 dividend of $0.33 per share[3] Future Plans - The proposed acquisition of SWK Holdings is expected to enhance the company's healthcare and life sciences exposure[3] - The company plans to hold a conference call on November 6, 2025, to discuss its third quarter financial results[25]

Financial Performance - The company reported net losses of $126.9 million and $384.0 million for the three and nine months ended September 30, 2025, respectively, compared to $107.2 million and $308.0 million for the same periods in 2024[95]. - As of September 30, 2025, the company had an accumulated deficit of $1.92 billion[95]. - The net loss for the three months ended September 30, 2025, was $126.90 million, an 18% increase compared to a net loss of $107.19 million in 2024[107]. - The company expects to continue incurring significant losses as it expands research and development activities and seeks regulatory approvals for product candidates[123]. - The company has not generated any product revenue to date and does not expect to until regulatory approval and commercialization of product candidates occur[122]. - For the nine months ended September 30, 2025, net cash used in operating activities was $314.1 million, driven by a net loss of $384.0 million[130]. - Cash, cash equivalents, and marketable securities amounted to $872.9 million as of September 30, 2025[117]. - The company had cash, cash equivalents, and marketable securities totaling $872.9 million as of September 30, 2025[136]. Research and Development - The company incurred significant research and development expenses, which are a major component of its operating expenses[97]. - Research and development expenses increased to $101.95 million for the three months ended September 30, 2025, up 4% from $98.24 million in the same period of 2024[108]. - Research and development expenses for the nine months ended September 30, 2025, totaled $320.87 million, an 8% increase from $296.65 million in 2024[112]. - The company is developing multiple product candidates, including tividenofusp alfa for MPS II and DNL126 for Sanfilippo syndrome, with ongoing clinical trials[91]. - The company plans to continue incurring significant expenses and operating losses as it advances its clinical programs and develops its TV platform[95]. Regulatory and Collaboration Efforts - The FDA granted Breakthrough Therapy Designation for tividenofusp alfa (DNL310) for the treatment of MPS II in January 2025, with a rolling submission of a Biologics License Application (BLA) completed in May 2025[93]. - The company announced that the FDA accepted the BLA for tividenofusp alfa for priority review, with a target action date of January 5, 2026, later extended to April 5, 2026[96]. - The company is actively pursuing collaborations with third parties, including Takeda and Biogen, to enhance its development and commercialization efforts[90]. - The company anticipates needing substantial additional resources to fund operations and meet future commitments[125]. Operating Expenses - General and administrative expenses rose to $35.48 million for the three months ended September 30, 2025, a 42% increase from $24.95 million in 2024[115]. - Total operating expenses for the three months ended September 30, 2025, were $137.43 million, reflecting a 12% increase from $123.19 million in 2024[107]. - The company anticipates an increase in general and administrative expenses due to preparations for the potential commercialization of Tividenofusp alfa[115]. Cash Flow and Financial Position - Net cash provided by investing activities was $234.5 million, primarily from $431.0 million in proceeds from marketable securities maturities[131]. - Cash used in financing activities was $2.9 million, consisting of $8.2 million in finance lease payments, partially offset by $5.2 million from stock option exercises[132]. - The company has raised approximately $754.4 million from public offerings of common stock through September 30, 2025[118]. Risks and Future Outlook - The company is exposed to interest rate risk, but a hypothetical 10% change in interest rates would not have a material impact on its financial statements[137]. - The company is also subject to foreign exchange risk due to transactions in currencies other than the U.S. dollar, primarily the Euro, Swiss Franc, and British Pound[138]. - Future funding requirements will depend on various factors, including regulatory approvals and the progress of clinical development activities[127]. - The company expects to incur substantial additional losses in the future due to ongoing research and development activities[125]. - Total undiscounted lease payment obligations amount to $57.4 million, with non-refundable purchase commitments of $39.4 million as of September 30, 2025[126].

Financial Performance - Total gross transaction value (GTV) increased 7% year over year to $3.9 billion, with strong performance across all sectors[5] - Total revenue rose 11% year over year to $1.1 billion, driven by higher service revenue and inventory sales revenue[5] - Service revenue increased 8% year over year to $845.0 million, with a service revenue take rate of 21.7%, up 20 basis points[6] - Net income increased 25% year over year to $95.2 million, while net income available to common stockholders rose 21% to $80.7 million[5] - Adjusted EBITDA grew 16% year over year to $327.7 million, reflecting strong operating leverage and growth initiatives[5] - For the third quarter ended September 30, 2025, Gross Transaction Value (GTV) was $3,893.8 million, an increase of 7.5% from $3,622.2 million in the same quarter of 2024[26] - Service revenue for the third quarter was $845.0 million, up 8.3% from $779.9 million year-over-year[26] - Total revenue for the nine months ended September 30, 2025, reached $3,387.3 million, compared to $3,142.6 million for the same period in 2024, reflecting a growth of 7.8%[26] - Net income for the third quarter was $95.2 million, a 25.3% increase from $76.0 million in the prior year[26] - Net income for the nine months ended September 30, 2025, was $318.2 million, an increase of 8.0% compared to $294.4 million in 2024[28] - Adjusted EBITDA for the nine months ended September 30, 2025, reached $1,020.1 million, up 7% from $956.7 million in the same period of 2024[38] - The company reported a 15% increase in net income for the twelve months ended September 30, 2025, totaling $436.6 million compared to $378.6 million in 2024[41] Revenue Sources - Inventory sales revenue surged 23% year over year to $247.7 million, benefiting from the inclusion of J.M. Wood Auction Co.[5] - The automotive sector GTV increased 6% year over year, while the commercial construction and transportation sector GTV rose 9%[10] - Total lots sold increased 2% year over year to 816.2 thousand, with notable growth in the automotive sector[11] Outlook and Guidance - The company updated its full-year 2025 GTV growth outlook to 0% to 1%, down from 0% to 3%[4] - Capital expenditures are projected to remain between $350 million and $400 million for the full year[4] Shareholder Returns - The company declared a quarterly cash dividend of $0.31 per common share, payable on December 17, 2025[17] Assets and Liabilities - Total current assets increased to $1,869.8 million as of September 30, 2025, compared to $1,714.8 million at the end of 2024[27] - Total liabilities stood at $6,260.2 million as of September 30, 2025, up from $6,090.6 million at the end of 2024[27] Earnings Per Share - Basic earnings per share available to common stockholders for the third quarter was $0.43, compared to $0.36 in the same quarter of 2024[26] - Diluted adjusted earnings per share available to common stockholders increased by 14% to $2.89 for the nine months ended September 30, 2025, compared to $2.54 in 2024[36] Cash Flow and Investments - Cash provided by operating activities for the nine months ended September 30, 2025, was $723.0 million, slightly down from $747.5 million in 2024[28] - The company incurred $163.6 million in cash outflows for the acquisition of J.M. Wood during the nine months ended September 30, 2025[28] - Total cash and cash equivalents at the end of the period was $753.3 million, down from $790.1 million at the end of the same period in 2024[28] - Net cash used in investing activities was $465.3 million for the nine months ended September 30, 2025, compared to $209.6 million in 2024[28] - The company reported a net cash used in financing activities of $226.5 million for the nine months ended September 30, 2025, a significant decrease from $491.6 million in 2024[28] Expenses - The company reported total operating expenses of $935.6 million for the third quarter, an increase from $828.9 million in the prior year[26] - Share-based payments expense increased by 49% to $61.2 million for the nine months ended September 30, 2025, compared to $41.1 million in 2024[36] - Share-based payments expense rose by 123% to $21.6 million in Q3 2025, compared to $9.7 million in Q3 2024[38] - Interest expense decreased by 16% to $48.2 million in Q3 2025, down from $57.2 million in Q3 2024[38] - Acquisition-related and integration costs dropped by 33% to $4.0 million in Q3 2025 from $6.0 million in Q3 2024[38] - Executive transition costs surged by 683% to $4.7 million in Q3 2025, compared to $0.6 million in Q3 2024[38] Debt and Financial Ratios - Adjusted net debt decreased by 7% to $1,967.5 million from $2,110.0 million year-over-year[41] - Short-term debt increased significantly by 134% to $73.6 million compared to $31.4 million in 2024[41] - The company's adjusted net debt/adjusted EBITDA ratio improved to 1.4x from 1.7x, indicating better financial flexibility[41] Other - An Australian subsidiary entered into an agreement to acquire Smith Broughton Pty Ltd for A$57.5 million ($38.0 million), expected to close in Q4 2025[18] - The company has not provided a reconciliation of Adjusted EBITDA outlook for fiscal 2025 to GAAP net income due to uncertainties in predicting non-GAAP adjustments[30]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 MVB Financial Corp. (Exact name of registrant as specified in its charter) FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 or ☐ TRANSITION REPORT UNDER SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________. Commission File Number: 001-38314 For the quarterly period ended September 30, 2025 West Virginia 20-0034461 ...

Financial Performance - For Q3 2025, the company reported net product sales of $973 million, a decrease of 46% compared to $1.8 billion in Q3 2024[115] - The net loss per share for Q3 2025 was $(0.51), contrasting with a net income per share of $0.03 in Q3 2024[115] - Total revenue for Q3 2025 decreased by $846 million, or 45%, to $1,016 million compared to Q3 2024[130] - Net product sales for Q3 2025 were $973 million, down $847 million, or 47%, from $1,820 million in Q3 2024[130] - Net loss for Q3 2025 was $200 million, compared to a net income of $13 million in Q3 2024, representing a decline of $213 million[130] - Interest income for Q3 2025 decreased by $30 million, or 29%, totaling $73 million compared to $103 million in Q3 2024[141] - The company expects a decline in net product sales for the full year 2025 due to lower expected vaccination rates and increased market competition[131] - The company incurred a net loss of $2.0 billion for the nine months ended September 30, 2025, following net losses of $3.6 billion and $4.7 billion for the years 2024 and 2023, respectively[156] Research and Development - The company has a pipeline of 30 development candidates across 40 programs, with 37 currently in clinical studies[110] - The Phase 3 trial for the investigational CMV vaccine (mRNA-1647) did not meet its primary efficacy endpoint, leading to the discontinuation of the congenital CMV clinical development program[119] - The company anticipates significant future capital requirements for ongoing research and development activities, including new vaccine candidates and digital capabilities[157] Product Approvals and Developments - The company has received approval for the 2025-2026 formula of Spikevax in 40 countries and for mNEXSPIKE in the U.S. for adults aged 65 and older[111] - mRESVIA has been approved for adults aged 60 and older in 40 countries, and for individuals aged 18 to 59 at increased risk in 31 of those countries[112] - The 2025-2026 formula of Spikevax generated over an 8-fold increase in LP.8.1-neutralizing antibodies in at-risk individuals aged 12-64 and all adults 65 and older[119] - The 2025-2026 formula of mNEXSPIKE generated over a 16-fold increase in LP.8.1-neutralizing antibodies in the same age groups[119] - The company plans to complete submissions for approval of its seasonal flu vaccine (mRNA-1010) by January 2026[119] Operational Metrics - Cash, cash equivalents, and investments decreased by $2.9 billion, or 30%, to $6.6 billion as of September 30, 2025, primarily due to a net cash outflow from operating activities of $2.8 billion[144] - Working capital decreased by $1.0 billion, or 17%, to $4.9 billion as of September 30, 2025, primarily due to a decrease in cash and current investments[145] - Net cash used in operating activities was $2.8 billion for the nine months ended September 30, 2025, consisting of a net loss of $2.0 billion and non-cash adjustments of $519 million[150] - Net cash provided by investing activities was $2.0 billion for the nine months ended September 30, 2025, driven by proceeds from maturities and sales of marketable securities of $6.4 billion[153] - Net cash provided by financing activities decreased by $47 million, or 80%, to $12 million for the nine months ended September 30, 2025, primarily due to a decrease in proceeds from issuance of common stock[155] Deferred Revenue - As of September 30, 2025, the company had deferred revenue of $144 million related to product sales, with $79 million expected to be realized in less than one year[128] - As of September 30, 2025, the company had $144 million in deferred revenue related to product sales[149] Cost Management - Research and development expenses for Q3 2025 decreased by $336 million, or 30%, totaling $801 million compared to $1,137 million in Q3 2024[135] - Selling, general and administrative expenses for Q3 2025 decreased by $13 million, or 5%, totaling $268 million compared to $281 million in Q3 2024[138] - Cost of sales for Q3 2025 was $207 million, a decrease of $307 million, or 60%, compared to $514 million in Q3 2024[133] - Total other income (expense), net improved to $4 million for the nine months ended September 30, 2025, compared to a total expense of $58 million in 2024, driven by lower equity investment losses and reduced interest expense[142] Manufacturing Capabilities - The mRNA manufacturing facilities in Australia and the UK became operational in Q3 2025, supporting domestic mRNA manufacturing and pandemic preparedness[113] - The company launched commercial sales of its RSV vaccine, mRESVIA, in Q3 2024 and expects limited contribution to total product sales in 2025[131]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _____________ Commission file number: 001-38273 ACM Research, Inc. (Exact Name of Registrant as Specified in Its Charter) D ...

Blend Announces Third Quarter 2025 Financial Results November 6, 2025 SAN FRANCISCO -- Blend Labs, Inc. (NYSE: BLND), a leading origination platform for digital banking solutions, today announced its third quarter 2025 financial results. Highlights Third quarter revenue was $32.9 million, a decrease of 1% compared to the third quarter of 2024. Software platform revenue was $30.5 million, down 2% year-over-year and Professional services revenue was $2.4 million, up 18% year- over-year. Total GAAP gross profi ...

Financial Performance - The company reported a consolidated revenue of $X billion for the quarter, representing a Y% increase compared to the previous quarter[1] - The gross margin improved to J%, reflecting better cost management and operational efficiencies[8] User Growth - User data showed an increase in active users to Z million, up A% year-over-year[2] Future Outlook - The company expects to achieve a revenue growth of B% for the next fiscal year, driven by new product launches and market expansion[3] - The company has set a performance guidance of I million barrels of oil equivalent (boe) per day for the upcoming quarter[7] Market Expansion - The company plans to expand its market presence in D regions, targeting a market share increase of E%[5] - A recent acquisition of F company is expected to enhance the company's capabilities in G sector, with an anticipated contribution of H million to annual revenue[6] Research and Development - Investment in R&D for new technologies increased by C%, focusing on sustainable energy solutions[4] Strategic Initiatives - The company is actively pursuing strategic partnerships to enhance its supply chain resilience and reduce operational risks[9] - Future capital expenditures are projected to be K billion, focusing on infrastructure and technology upgrades[10] Organizational Structure - References to "APA" and "Apache" indicate the company's consolidated subsidiaries, highlighting the structure of the organization[18]